_version_ |
1797287168546177024
|
collection |
DOAJ
|
first_indexed |
2024-03-07T18:29:03Z
|
format |
Article
|
id |
doaj.art-7f57d4ed24b44c3c86d47565b31bec48
|
institution |
Directory Open Access Journal
|
issn |
2572-9241
|
language |
English
|
last_indexed |
2024-03-07T18:29:03Z
|
publishDate |
2018-10-01
|
publisher |
Wiley
|
record_format |
Article
|
series |
HemaSphere
|
spelling |
doaj.art-7f57d4ed24b44c3c86d47565b31bec482024-03-02T06:41:27ZengWileyHemaSphere2572-92412018-10-0121210.1097/01.HS9.0000547845.05525.e3201810003-00002T005 (0077) TRABECTEDIN INHIBITS CLASSICAL HODGKIN LYMPHOMA GROWTH, MONOCYTES IMMUNOSUPPRESSIVE POLARIZATION BY TUMOR CELLS AND SYNERGIZES WITH THE CCR5-ANTAGONIST MARAVIROChttp://journals.lww.com/10.1097/01.HS9.0000547845.05525.e3
|
spellingShingle |
T005 (0077) TRABECTEDIN INHIBITS CLASSICAL HODGKIN LYMPHOMA GROWTH, MONOCYTES IMMUNOSUPPRESSIVE POLARIZATION BY TUMOR CELLS AND SYNERGIZES WITH THE CCR5-ANTAGONIST MARAVIROC
HemaSphere
|
title |
T005 (0077) TRABECTEDIN INHIBITS CLASSICAL HODGKIN LYMPHOMA GROWTH, MONOCYTES IMMUNOSUPPRESSIVE POLARIZATION BY TUMOR CELLS AND SYNERGIZES WITH THE CCR5-ANTAGONIST MARAVIROC
|
title_full |
T005 (0077) TRABECTEDIN INHIBITS CLASSICAL HODGKIN LYMPHOMA GROWTH, MONOCYTES IMMUNOSUPPRESSIVE POLARIZATION BY TUMOR CELLS AND SYNERGIZES WITH THE CCR5-ANTAGONIST MARAVIROC
|
title_fullStr |
T005 (0077) TRABECTEDIN INHIBITS CLASSICAL HODGKIN LYMPHOMA GROWTH, MONOCYTES IMMUNOSUPPRESSIVE POLARIZATION BY TUMOR CELLS AND SYNERGIZES WITH THE CCR5-ANTAGONIST MARAVIROC
|
title_full_unstemmed |
T005 (0077) TRABECTEDIN INHIBITS CLASSICAL HODGKIN LYMPHOMA GROWTH, MONOCYTES IMMUNOSUPPRESSIVE POLARIZATION BY TUMOR CELLS AND SYNERGIZES WITH THE CCR5-ANTAGONIST MARAVIROC
|
title_short |
T005 (0077) TRABECTEDIN INHIBITS CLASSICAL HODGKIN LYMPHOMA GROWTH, MONOCYTES IMMUNOSUPPRESSIVE POLARIZATION BY TUMOR CELLS AND SYNERGIZES WITH THE CCR5-ANTAGONIST MARAVIROC
|
title_sort |
t005 0077 trabectedin inhibits classical hodgkin lymphoma growth monocytes immunosuppressive polarization by tumor cells and synergizes with the ccr5 antagonist maraviroc
|
url |
http://journals.lww.com/10.1097/01.HS9.0000547845.05525.e3
|